Based on the Intracellular Th stock forecast from 14 analysts, the average analyst target price for Intracellular Th is USD 98.75 over the next 12 months. Intracellular Th’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Intracellular Th is Neutral, which is based on 3 positive signals and 3 negative signals. At the last closing, Intracellular Th’s stock price was USD 87.63. Intracellular Th’s stock price has changed by -3.18% over the past week, +18.68% over the past month and +54.55% over the last year.
No recent analyst target price found for Intracellular Th
No recent average analyst rating found for Intracellular Th
Company Overview Intracellular Th
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. Read Less
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mech...Read More
Frequently Asked Questions About Intracellular Th (ITCI) Stock
Based on ratings from 14 analysts Intracellular Th's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 21 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on ITCI's stock to indicate if its a good dividend stock.
Based on targets from 14 analysts, the average taret price for ITCI is USD 98.75 over the next 12 months. The maximum analyst target price is USD 130 while the minimum anlayst target price is USD 77.
Unfortunately we do not have enough data on ITCI's stock to indicate if its overvalued.
The last closing price of ITCI's stock was USD 87.63.
The most recent market capitalization for ITCI is USD 9.17B.
Based on targets from 14 analysts, the average taret price for ITCI is projected at USD 98.75 over the next 12 months.
This means that ITCI's stock price may go up by +12.69% over the next 12 months.
We can't find any ETFs which contains Intracellular Th's stock.
As per our most recent records Intracellular Th has 610 Employees.
Intracellular Th's registered address is 430 East 29th Street, New York, NY, United States, 10016.
You can get more information about it from Intracellular Th's website at https://www.intracellulartherapies.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Intracellular Th (ITCI) Stock
Based on ratings from 14 analysts Intracellular Th's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 21 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on ITCI's stock to indicate if its a good dividend stock.
Based on targets from 14 analysts, the average taret price for ITCI is USD 98.75 over the next 12 months. The maximum analyst target price is USD 130 while the minimum anlayst target price is USD 77.
Unfortunately we do not have enough data on ITCI's stock to indicate if its overvalued.
The last closing price of ITCI's stock was USD 87.63.
The most recent market capitalization for ITCI is USD 9.17B.
Based on targets from 14 analysts, the average taret price for ITCI is projected at USD 98.75 over the next 12 months.
This means that ITCI's stock price may go up by +12.69% over the next 12 months.
We can't find any ETFs which contains Intracellular Th's stock.
As per our most recent records Intracellular Th has 610 Employees.
Intracellular Th's registered address is 430 East 29th Street, New York, NY, United States, 10016.
You can get more information about it from Intracellular Th's website at https://www.intracellulartherapies.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ITCI !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
